Bodyport

Day 1 at THT is complete & what an exciting start! The Future of Remote Patient Monitoring (RPM) is here, and it’s incredible to see the innovative research and clinical advancements shaping patient care. If you're at THT, don’t miss our abstract tomorrow, February 12th at 8am!  Join Kivanc Ozonat, PhD, Head of Data Science at Bodyport, as he shares insights on Bioelectrical Phase Angle for Heart Failure Hospitalization and Readmission Risk Stratification. Stop by, say hello, and let’s discuss the next frontier of heart failure management! Kivanc OzonatBrian CarrollHeidi Ann Svejda, MSJohn LipmanJay PanditCorey Centen@sarahsmith

Don’t miss this practical session coming up with Dr Marat Fudim MD MHS a week today! https://lnkd.in/eKZ2famu

♥️ Bodyport + Remote Heart Care = A Match Made in Heaven ♥️   During American Heart Month and especially this Heart Awareness Week, we’re celebrating partnerships that truly matter. With our FDA-cleared Fluid Management Platform, providers can stay closer to their heart failure patients, delivering proactive care and improving outcomes. We're proud to partner with amazing health care professionals and empower patients - interested to find out more? Click the link below to schedule a product demo or meet with our team. @partnerships@bodyport.com

📢 Our Abstract on Phase Angle in Heart Failure Has Been Accepted at THT 2025! We’re thrilled to announce that research on Phase Angle has been accepted for abstract at the Technology & Heart Failure Therapeutics (THT) Conference! Kivanc Ozonat, PhD, Head of Data Science, Bodyport Inc. said; 'I am excited to share our innovative research at THT in Boston on February 12th. Bioelectrical phase angle is independently associated with heart failure hospitalization and readmission risk. The non-invasive and painless measurement is taken at home in approximately 20 seconds with the FDA-cleared Bodyport Cardiac Scale.' Let’s connect at THT or virtually! Reach out at https://lnkd.in/evvkVvgT to schedule a meeting. #THT2025 #HeartFailureCare #HeartCareInnovation #PhaseAngleResearch

📢 Our Abstract on Phase Angle in Heart Failure Has Been Accepted at THT 2025! We’re thrilled to announce that research on Phase Angle has been accepted for abstract at the Technology & Heart Failure Therapeutics (THT) Conference! Kivanc Ozonat, PhD, Head of Data Science, Bodyport Inc. said; 'I am excited to share our innovative research at THT in Boston on February 12th. Bioelectrical phase angle is independently associated with heart failure hospitalization and readmission risk. The non-invasive and painless measurement is taken at home in approximately 20 seconds with the FDA-cleared Bodyport Cardiac Scale.' Let’s connect at THT or virtually! Reach out at https://lnkd.in/evvkVvgT to schedule a meeting. #THT2025 #HeartFailureCare #HeartCareInnovation #PhaseAngleResearch

Heading to #THT2025? Let’s Connect! We’re excited to attend the upcoming THT Heart Technology Conference Feb 11-13 in Boston and explore the latest innovations in heart care technology. Our team will be there and ready to meet with providers who are interested in transforming heart failure care with Bodyport's FDA-cleared Fluid Management Platform. Don’t miss the opportunity to discuss how our solution can help improve outcomes for your patients. Schedule a meeting directly here: East: https://lnkd.in/ecna4XfE or West: https://lnkd.in/ehjFvyk8 or email partnerships@bodyport.com. Let’s shape the future of heart care together! #THT2025 #HeartFailureCare #Hearthealth #Healthtech #HeartCareInnovation

💡 Women Matter in Heart Failure Research 💡 The SCALE-HF 1 study stood out for its inclusion of a significant proportion of women, addressing a critical gap in heart failure research traditionally dominated by male participants (source: Parwani PJ, Van Spall HGC, Mamas M Representation of women in heart failure trials: does it matter? Heart 2022;108:1508-1509). Ensuring women were adequately represented in overall results, we demonstrated that Bodyport’s Fluid Management Care Platform offers effective monitoring, accurately predicting events 14 days earlier, doubling detection rates compared to weight-based monitoring, and significantly reducing false alerts. Explore this groundbreaking study in the Journal of Cardiac Failure https://lnkd.in/erVHG5bV. Interested in expanding your heart failure care strategies? Let’s connect at partnerships@bodyport.com. #HeartHealthJourney #WomenInResearch #HFSA

🚨 In heart failure care, timing is everything. Early intervention can mean the difference between managing a patient at home or sending them to the hospital. With Bodyport’s Fluid Monitoring Platform, providers are getting the actionable insights they need to stay ahead. As one provider shared: "With Bodyport, we’re able to accurately monitor fluid trends and be alerted up to 14 days in advance of patients developing an acute exacerbation of Cardiac Heart Failure, before they get to the point of hospitalization. By getting this information in time, we’re able to treat at home with diuretics or identify an incident due to diet or missed medication so we can get them on the right regimen again." Up to 14 days. That’s time to act, to adjust care plans, and to keep patients safe at home. Connect with us to learn how to access our simple solution for your patients @partnerships@bodyport.com. #HeartFailureCare #RemoteMonitoring #DigitalHealth #ProactiveCare

💡 Women Matter in Heart Failure Research 💡 The SCALE-HF 1 study stood out for its inclusion of a significant proportion of women, addressing a critical gap in heart failure research traditionally dominated by male participants (source: Parwani PJ, Van Spall HGC, Mamas M Representation of women in heart failure trials: does it matter? Heart 2022;108:1508-1509). Ensuring women were adequately represented in overall results, we demonstrated that Bodyport’s Fluid Management Care Platform offers effective monitoring, accurately predicting events 14 days earlier, doubling detection rates compared to weight-based monitoring, and significantly reducing false alerts. Explore this groundbreaking study in the Journal of Cardiac Failure https://lnkd.in/erVHG5bV. Interested in expanding your heart failure care strategies? Let’s connect at partnerships@bodyport.com. #HeartHealthJourney #WomenInResearch #HFSA

💡 Streamlining Remote Heart Care with RPM Codes 💡 Are you leveraging Remote Patient Monitoring (RPM) codes for non-invasive heart failure management? With Bodyport’s Fluid Management Care Platform, we’re helping providers seamlessly expand their RPM programs to include innovative, non-invasive solutions that fit within existing billing frameworks*. The American College of Cardiology's Remote Patient Monitoring Management Guide (pages 15-17 https://lnkd.in/eGAYgW_Z) offers a comprehensive overview of RPM and CPT codes, making it easier to integrate devices like ours into your practice. If you’re looking to expand your RPM strategy with a scalable, non-invasive FDA-cleared solution for heart failure care, we’d love to connect. Contact us at partnerships@bodyport.com to learn more. *Reimbursement codes and their application are subject to official payer guidance and may vary by jurisdiction and provider circumstances.